Citius Pharmaceuticals Book Value 2011-2026 | CTXR

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Citius Pharmaceuticals

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
74.1 M	91.4 M	103 M	133 M	33.7 M	24.4 M	27.9 M	21.9 M	16.8 M	-635 K	-742 K	-14.7 K	-45.8 K	-23.8 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
133 M	-742 K	37.5 M

Quarterly Book Value Citius Pharmaceuticals

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
93.5 M	77.5 M	67.6 M	63.6 M	68.9 M	74.1 M	86.3 M	80 M	85.3 M	91.4 M	98.3 M	91.8 M	101 M	103 M	110 M	118 M	125 M	133 M	137 M	133 M	25.8 M	33.7 M	33.7 M	33.7 M	20.4 M	27.2 M	24.4 M	24.4 M	28.1 M	31.1 M	31.1 M	31.1 M	28.5 M	24.4 M	24.4 M	24.4 M	21.5 M	22 M	22 M	22 M	347 K	742 K	742 K	742 K	823 K	-742 K	1.56 M	1.56 M	-2.9 M	-	-	5.95 K	99	135	135	135	216	212	212	212

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
137 M	-2.9 M	42.7 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Regeneron Pharmaceuticals REGN	31.3 B	$ 742.1	-1.93 %	$ 77.6 B	USA
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
AbbVie ABBV	134 B	$ 211.9	0.37 %	$ 375 B	USA
Replimune Group REPL	416 M	$ 7.26	-3.71 %	$ 585 M	USA
AbCellera Biologics ABCL	967 M	$ 3.28	-2.24 %	$ 980 M	Canada
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	39.9 M	-	1.93 %	$ 17.4 M	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Rigel Pharmaceuticals RIGL	391 M	$ 26.28	-0.34 %	$ 473 M	USA
Aileron Therapeutics ALRN	16.9 M	-	10.36 %	$ 9.8 M	USA
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Arena Pharmaceuticals ARNA	785 M	-	-6.81 %	$ 3.04 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Avenue Therapeutics ATXI	1.86 M	-	-52.27 %	$ 4.45 M	USA
Avidity Biosciences RNA	1.69 B	$ 13.07	-0.23 %	$ 1.8 B	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Atreca BCEL	78.4 M	-	-11.76 %	$ 5.79 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
bluebird bio BLUE	195 M	-	-	$ 546 M	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Rhythm Pharmaceuticals RYTM	270 M	$ 77.56	-5.31 %	$ 5.04 B	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Avid Bioservices CDMO	60.9 M	-	-	$ 789 M	USA
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Adaptive Biotechnologies Corporation ADPT	225 M	$ 12.27	-12.11 %	$ 1.86 B	USA
BeiGene, Ltd. BGNE	4.36 B	-	0.49 %	$ 251 B	Cayman-islands
SIGA Technologies SIGA	199 M	$ 5.36	7.96 %	$ 383 M	USA
Silence Therapeutics plc SLN	9.06 M	$ 4.92	-7.34 %	$ 622 M	Britain
SELLAS Life Sciences Group SLS	70.9 M	$ 4.47	-9.69 %	$ 487 M	USA
BioDelivery Sciences International BDSI	188 M	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	57.1 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	286 M	-	-	$ 3.74 B	USA
Enlivex Therapeutics Ltd. ENLV	23.6 M	$ 1.08	-1.38 %	$ 22.2 M	Israel
Enochian Biosciences ENOB	-21.3 M	-	-	$ 40.5 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Summit Therapeutics SMMT	659 M	$ 16.59	-3.88 %	$ 12.4 B	Britain
Spruce Biosciences SPRB	42.5 M	$ 62.07	-10.19 %	$ 47.6 M	USA